Drugs / Lamivudine/Zidovudine
last change Oct 2007 re-read 2 minutes ago

Lamivudine/Zidovudine

also known as 3TC/ZDV · Combivir
Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00001094 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2007-10-29 Gilead Sciences Gilead Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients gilead.com
2007-07-23 Gilead Sciences 144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney gilead.com
2006-12-15 Gilead Sciences 96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome gilead.com
2006-08-14 Gilead Sciences 96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference gilead.com
2006-01-18 Gilead Sciences Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of Combination HIV Therapy Published in New England Journal of Medicine gilead.com

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Lamivudine/Zidovudine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001094
Known as 3TC/ZDV “combination lamivudine/zidovudine (3TC/ZDV, Combivir)” NCT00001094
Known as Combivir “combination lamivudine/zidovudine (3TC/ZDV, Combivir)” NCT00001094